Merck KGaA secures CRISPR patent in China

China’s State Intellectual Property Office (SIPO) has granted Merck KGaA a patent covering its CRISPR technology used in a genomic-integration method for eukaryotic cells.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

Merck KGaA secures CRISPR patents in Japan and Singapore

27 November 2019 The Japan Patent Office and the Intellectual Property Office of Singapore have each granted Merck KGaA a patent covering the use of paired CRISPR nickases.

Americas

GSK and Merck KGaA unite in €3.7bn immunotherapy deal

6 February 2019 UK headquartered GSK has made another move in the oncology space, signing a potential €3.7 billion immunotherapy deal with Germany-based Merck KGaA.

Asia-Pacific

Merck granted its first CRISPR patent in Australia

16 June 2017 Merck has been granted its first CRISPR technology patent by the Australian Patent Office.